San Diego, CA - August 7, 2003 -TargeGen, Inc., a biopharmaceutical company focusing on novel small molecule drugs for the treatment of ischemic diseases and cancer, today announced the appointment of Mark R. Green, M.D., to its Scientific Advisory Board.

Dr. Green currently serves as Professor of Medicine and Gilbreth Professor of Clinical Oncology at the Medical University of South Carolina (MUSC). Prior to joining MUSC, Dr. Green served from 1985-90 as Director of the UCSD Cancer Center in San Diego. Dr. Green has more than 300 scientific publications to his credit. He received his B.A. (Magna Cum Laude) at Harvard University and an M.D. from Harvard Medical School. He completed post-graduate training in Internal Medicine at the Beth Israel Hospital in Boston and at Stanford University Medical Center. He took his oncology subspecialty training at the National Cancer Institute and Stanford.

Dr. Green has served as the chair of the Respiratory Committee of the CALGB, an NCI funded nationwide, multi-specialty cancer clinical trials group, since 1985. He is currently vice-chairman of the CALGB. Between 1989 and 1995 he was a member of the Subspecialty Board of Medical Oncology of the American Board of Internal Medicine. He served as chair of the Medical Oncology Board from 1995-99.

"We are honored to have someone of Dr. Green's stature in the field of clinical oncology join our Scientific Advisory Board," said Peter G. Ulrich, President and CEO of TargeGen. "TargeGen is rapidly advancing its preclinical oncology program into human clinical trials. Mark's talent and wealth of experience in clinical research in the cancer field will certainly be of great benefit to us as we approach our first human cancer trials"

About TargeGen, Inc.

TargeGen, Inc., is a privately held vascular biology-focused biopharmaceutical company which initiated operations in March, 2002. The Company is developing novel small molecule therapeutics to treat cancer and ischemic diseases by regulating certain biochemical processes including vascular proliferation and vascular permeability.

For additional information, contact:

Peter G. Ulrich, President & CEO
TargeGen, Inc.
9393 Towne Centre Drive
Suite 120
San Diego, CA 92121
Tel 858-678-0760
Fax 858-678-0762
ulrich@targegen.com
http://www.targegen.com